Montelukast is the most potent leukotriene receptor antagonist (LTRA) and achieves its therapeutic effect in asthma by selectively blocking the cysteinyl leukotriene receptor type 1 (CysLT1R) on the smooth muscle of the lungs [32,33]. The gene discussed is CYSLTR1; the disease is asthma.